Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?

doi:10.3748/wjg.v13.i36.4903

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 36

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1911)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

209

HTML

1353

Figures (1-2)

161

Tables (1-2)

188

Sum=1911

Sep 28, 2007 (publication date) through Jul 23, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Sep 28, 2007; 13(36): 4903-4908
Published online Sep 28, 2007. doi: 10.3748/wjg.v13.i36.4903

Full Size Figure Download Figure

Figure 1 Behaviour of the applied quantitative liver function test in 35 patients treated with combined antiviral therapy. TOSCA: total overnight salivary caffeine assessment. The knurled line shows which groups are significantly different in the values of TOSCA, in respect to the basal ones; ANCOVA (repeated measure) test, P = 0.0001.

Citation: Tarantino G, Gentile A, Capone D, Basile V, Tarantino M, Minno MNDD, Cuocolo A, Conca P. Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression? World J Gastroenterol 2007; 13(36): 4903-4908
URL: https://www.wjgnet.com/1007-9327/full/v13/i36/4903.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i36.4903